205 related articles for article (PubMed ID: 27009878)
1. Cisplatin treatment increases stemness through upregulation of hypoxia-inducible factors by interleukin-6 in non-small cell lung cancer.
Zhang F; Duan S; Tsai Y; Keng PC; Chen Y; Lee SO; Chen Y
Cancer Sci; 2016 Jun; 107(6):746-54. PubMed ID: 27009878
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer.
Zhang F; Shen M; Yang L; Yang X; Tsai Y; Keng PC; Chen Y; Lee SO; Chen Y
Cancer Biol Ther; 2017 Aug; 18(8):606-615. PubMed ID: 28686074
[TBL] [Abstract][Full Text] [Related]
3. IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules.
Duan S; Tsai Y; Keng P; Chen Y; Lee SO; Chen Y
Oncotarget; 2015 Sep; 6(29):27651-60. PubMed ID: 26313152
[TBL] [Abstract][Full Text] [Related]
4. A FASN-TGF-β1-FASN regulatory loop contributes to high EMT/metastatic potential of cisplatin-resistant non-small cell lung cancer.
Yang L; Zhang F; Wang X; Tsai Y; Chuang KH; Keng PC; Lee SO; Chen Y
Oncotarget; 2016 Aug; 7(34):55543-55554. PubMed ID: 27765901
[TBL] [Abstract][Full Text] [Related]
5. JARID2 promotes stemness and cisplatin resistance in non-small cell lung cancer via upregulation of Notch1.
Wang Q; Wu J; Wei H; Huang H; Huang Y; Fang H; Gong X; Sun J; Wu Y; Lei C; Yu J; Hu D
Int J Biochem Cell Biol; 2021 Sep; 138():106040. PubMed ID: 34246759
[TBL] [Abstract][Full Text] [Related]
6. IL-6 promotes growth and epithelial-mesenchymal transition of CD133+ cells of non-small cell lung cancer.
Lee SO; Yang X; Duan S; Tsai Y; Strojny LR; Keng P; Chen Y
Oncotarget; 2016 Feb; 7(6):6626-38. PubMed ID: 26675547
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 blockade attenuates lung cancer tissue construction integrated by cancer stem cells.
Ogawa H; Koyanagi-Aoi M; Otani K; Zen Y; Maniwa Y; Aoi T
Sci Rep; 2017 Sep; 7(1):12317. PubMed ID: 28951614
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway.
Shen M; Xu Z; Xu W; Jiang K; Zhang F; Ding Q; Xu Z; Chen Y
J Exp Clin Cancer Res; 2019 Apr; 38(1):149. PubMed ID: 30961670
[TBL] [Abstract][Full Text] [Related]
9. NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathway.
Jiang P; Xu H; Xu C; Chen A; Chen L; Zhou M; Haq IU; Wu X; Mariyam Z; Feng Q
Chem Biol Interact; 2018 Dec; 296():154-161. PubMed ID: 30291867
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
11. Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma.
Hao C; Liu G; Tian G
Ther Adv Respir Dis; 2019; 13():1753466619866097. PubMed ID: 31368411
[TBL] [Abstract][Full Text] [Related]
12. EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells.
Jiang P; Xu C; Chen L; Chen A; Wu X; Zhou M; Haq IU; Mariyam Z; Feng Q
Mol Carcinog; 2018 Dec; 57(12):1835-1844. PubMed ID: 30182373
[TBL] [Abstract][Full Text] [Related]
13. Synergistic Roles of Curcumin in Sensitising the Cisplatin Effect on a Cancer Stem Cell-Like Population Derived from Non-Small Cell Lung Cancer Cell Lines.
Abdul Satar N; Ismail MN; Yahaya BH
Molecules; 2021 Feb; 26(4):. PubMed ID: 33670440
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
[TBL] [Abstract][Full Text] [Related]
15. Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1α mediated XPC transcription.
Liu Y; Wang X; Li W; Xu Y; Zhuo Y; Li M; He Y; Wang X; Guo Q; Zhao L; Qiang L
Oncogene; 2020 Nov; 39(45):6893-6905. PubMed ID: 32978517
[TBL] [Abstract][Full Text] [Related]
16. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
[TBL] [Abstract][Full Text] [Related]
17. Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition.
Yang L; Shen M; Xu LJ; Yang X; Tsai Y; Keng PC; Chen Y; Lee SO
Sci Rep; 2017 Aug; 7(1):7958. PubMed ID: 28801607
[TBL] [Abstract][Full Text] [Related]
18. The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer.
Fernandez HR; Gadre SM; Tan M; Graham GT; Mosaoa R; Ongkeko MS; Kim KA; Riggins RB; Parasido E; Petrini I; Pacini S; Cheema A; Varghese R; Ressom HW; Zhang Y; Albanese C; Üren A; Paige M; Giaccone G; Avantaggiati ML
Cell Death Differ; 2018 Jul; 25(7):1239-1258. PubMed ID: 29651165
[TBL] [Abstract][Full Text] [Related]
19. PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness.
Chen MJ; Wu DW; Wang YC; Chen CY; Lee H
Sci Rep; 2016 Oct; 6():34933. PubMed ID: 27713506
[TBL] [Abstract][Full Text] [Related]
20. MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway.
Huang G; Lou T; Pan J; Ye Z; Yin Z; Li L; Cheng W; Cao Z
Aging (Albany NY); 2019 Apr; 11(7):2138-2150. PubMed ID: 30981205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
